{"nctId":"NCT00834106","briefTitle":"Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)","startDateStruct":{"date":"2008-12-31","type":"ACTUAL"},"conditions":["HPV Infections"],"count":3006,"armGroups":[{"label":"qHPV","type":"EXPERIMENTAL","interventionNames":["Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Comparator: placebo (unspecified)"]}],"interventions":[{"name":"Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine","otherNames":["Gardasil â„¢","V501"]},{"name":"Comparator: placebo (unspecified)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy women between the ages of 20 and 45\n* Have used effective contraception for 2 weeks prior to starting in the study\n* Does not have a temperature within 24 hours before the first injection\n\nExclusion Criteria:\n\n* Prior history of genital warts\n* More than 4 lifetime sexual partners\n* Have undergone hysterectomy\n* Have active cervical disease or history of cervical disease","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"20 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Base Study: Combined Incidence of 6-Month Persistent Infection, Cervical Intraepithelial Neoplasia (CIN+), and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 45 Year Old Participants (Test of Hypothesis)","description":"The endpoint included pathology panel consensus diagnosis of 6-month persistent infection, CIN+ (including CIN grade 1, 2, or 3, cervical adenocarcinoma in situ (AIS), and cervical cancer), or external genital lesions related to HPV Types 6, 11, 16, or 18 detected by polymerase chain reaction (PCR) in an adjacent section from the same tissue block.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"1.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Base Study: Combined Incidence of 6-Month Persistent Infection, CIN+, and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 26 Years Old Participants (Test of Hypothesis)","description":"The endpoint included pathology panel consensus diagnosis of 6-month persistent infection, CIN+ (including CIN grade 1, 2, or 3, cervical adenocarcinoma in situ (AIS), and cervical cancer), or external genital lesions related to HPV Types 6, 11, 16, or 18 detected by PCR in an adjacent section from the same tissue block.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"1.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Entire Study: Combined Incidence of CIN2+ Related to HPV Types 16 or 18 in 20 to 45 Year Old Participants (End of Study Test of Hypothesis)","description":"The endpoint included pathology panel consensus diagnosis of CIN2+ (including CIN grade 2 or 3, AIS, and cervical cancer) related to HPV Types 16 or 18 detected by PCR in an adjacent section from the same tissue block.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Base Study: Percentage of Participants With One or More Solicited Injection-site Adverse Events","description":"An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the sponsor's product, is also an AE. Injection-site AEs were prompted on the Vaccination Report Card (VRC), which was completed by the participant for 15 days after each vaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.6","spread":null},{"groupId":"OG001","value":"27.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Base Study: Percentage of Participants With One or More Systemic Adverse Events","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the sponsor's product, is also an AE.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.4","spread":null},{"groupId":"OG001","value":"48.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Base Study: Percentage of Participants Discontinued From Study Vaccination Due to an Adverse Event","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the sponsor's product, is also an AE.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Entire Study: Percentage of Participants With One or More Vaccine-related Serious Adverse Events","description":"A serious adverse event (SAE) is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is an overdose or, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention. Related SAEs were those deemed possibly, probably, or definitely related to study vaccine or a study procedure.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Entire Study: Percentage of Participants Who Died","description":"The percentage of participants who died on study due to any cause, whether or not related to the investigational product, were reported for each arm","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Entire Study: Combined Incidence of 12-Month Persistent Infection, CIN+, and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 45 Year Old Participants (End of Study Update)","description":"The endpoint included pathology panel consensus diagnosis of 12-month persistent infection, CIN+ (including CIN grade 1, 2, or 3, cervical adenocarcinoma in situ (AIS), and cervical cancer), or external genital lesions related to HPV Types 6, 11, 16, or 18 detected by PCR in an adjacent section from the same tissue block.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Entire Study: Combined Incidence of 12-Month Persistent Infection, CIN+, and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 26 Year Old Participants (End of Study Update)","description":"The endpoint included pathology panel consensus diagnosis of 12-month persistent infection, CIN+ (including CIN grade 1, 2, or 3, cervical adenocarcinoma in situ (AIS), and cervical cancer), or external genital lesions related to HPV Types 6, 11, 16, or 18 detected by PCR in an adjacent section from the same tissue block.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":38,"n":1499},"commonTop":["Injection Site Pain","Pyrexia","Fatigue","Headache","Myalgia"]}}}